Sez6l2 is an important regulator of drug-resistant cells and tumor spheroid cells in lung adenocarcinoma

Jang Seok Lee, Hee Yeon Kim, Bomyi Won, Sang Won Kang, Yong Nyun Kim, Hyonchol Jang

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Many lung cancer deaths result from relapses in distant organs, such as the brain or bones, after standard chemotherapy. For cancer cells to spread to other organs, they must survive as circulating tumor cells (CTCs) in blood vessels. Thus, reducing distant recurrence after chemotherapy requires simultaneously inhibiting drug resistance and CTC survival. Here, we investigated the molecular pathways and genes that are commonly altered in drug-resistant lung cancer cells and lung tumor spheroid (TS) cells. First, RNA sequencing was performed in drug-resistant cells and TS cells originating from H460 and A549 lung cancer cells. Bioinformatic pathway analysis showed that cell cycle-related pathways were downregulated in drug-resistant cells, and cholesterol biosynthesis-related pathways were upregulated in TS cells. Seizure-related 6 homolog-like 2 (SEZ6L2) was selected as a gene that was commonly upregulated in both drug-resistant cells and TS cells, and that showed elevated expression in samples from lung adenocarcinoma patients. Second, the protein expression of SEZ6L2 was analyzed by flow cytometry. The proportions of SEZ6L2 positive cells among both drug-resistant cells and TS cells was increased. Finally, as SEZ6L2 is a transmembrane protein with an extracellular region, the function of SEZ6L2 was disrupted by treatment with an anti-SEZ6L2 antibody. Treatment with the anti-SEZ6L2 antibody reduced drug resistance and TS formation. Overall, our data showed that SEZ6L2 plays an important role in drug resistance and TS formation and may be a therapeutic target for reducing distant recurrence of lung adenocarcinoma.

Original languageEnglish
Article number500
Pages (from-to)1-12
Number of pages12
Issue number11
StatePublished - Nov 2020

Bibliographical note

Funding Information:
Funding: This research was funded by the National Cancer Center, Korea, grant number NCC-1810292, 1910033 and 2010272.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.


  • Circulating tumor cell
  • Distant recurrence
  • Drug resistance
  • Lung adenocarcinoma
  • SEZ6L2
  • Tumor spheroid


Dive into the research topics of 'Sez6l2 is an important regulator of drug-resistant cells and tumor spheroid cells in lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this